.Attributes Medication, Published online: 16 October 2024 doi:10.1038/ s41591-024-03348-1Publisher Modification: Allogeneic CD5-specific CAR-T treatment for relapsed/refractory T-ALL: a stage 1 trial.
Universal Knowledge Trends Insights Daily
Daily insights on trends in universal knowledge covering news, finance, technology, health, and lifestyle.
.Attributes Medication, Published online: 16 October 2024 doi:10.1038/ s41591-024-03348-1Publisher Modification: Allogeneic CD5-specific CAR-T treatment for relapsed/refractory T-ALL: a stage 1 trial.